Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cryoport, Inc. stock logo
CYRX
Cryoport
$6.68
-0.7%
$5.95
$4.58
$13.68
$334.92M1.92543,066 shs475,735 shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$11.83
+0.8%
$10.36
$6.36
$47.45
$1.34B1.191.68 million shs2.19 million shs
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
$25.17
+3.0%
$21.19
$13.22
$62.74
$1.44B-1.69932,879 shs826,116 shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$21.25
-0.4%
$23.49
$18.53
$51.61
$1.35B1.28780,251 shs955,320 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cryoport, Inc. stock logo
CYRX
Cryoport
+4.02%-3.65%+19.75%0.00%-52.10%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.34%+3.69%+49.55%-15.60%-60.04%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
+2.56%-8.91%+29.26%+0.16%-32.27%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
+0.66%-3.16%-1.20%-22.32%-50.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cryoport, Inc. stock logo
CYRX
Cryoport
2.8547 of 5 stars
4.41.00.00.02.22.50.6
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.6239 of 5 stars
4.52.00.00.04.03.30.0
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
2.1523 of 5 stars
3.51.00.00.03.11.70.6
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
3.4581 of 5 stars
4.63.00.00.03.22.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0064.67% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.07
Buy$46.85295.99% Upside
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
3.00
Buy$78.00209.89% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
3.10
Buy$63.33198.04% Upside

Current Analyst Ratings Breakdown

Latest CYRX, VERA, DYN, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $75.00
5/9/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $38.00
5/9/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.00
5/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
5/5/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$75.00
5/2/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
4/22/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cryoport, Inc. stock logo
CYRX
Cryoport
$214.83M1.56$0.39 per share16.95$9.45 per share0.71
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$1.49 per shareN/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$9.77 per shareN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$1.94 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%N/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%N/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%N/A

Latest CYRX, VERA, DYN, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/8/2025Q1 2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
5/8/2025Q1 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.75-$0.81-$0.06-$0.81N/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
3/4/2025Q4 2024
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.92-$0.88+$0.04-$0.88N/AN/A
2/27/2025Q4 2024
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$0.23-$0.22+$0.01-$0.22N/AN/A
2/26/2025Q4 2024
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.83-$0.72+$0.11-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
17.02
17.02
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/A
27.63
27.63
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.17
13.76
13.76

Institutional Ownership

CompanyInstitutional Ownership
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
91.78%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%

Insider Ownership

CompanyInsider Ownership
Cryoport, Inc. stock logo
CYRX
Cryoport
10.00%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
14.14%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
9.43%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
16.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million80.63 millionOptionable
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
13657.34 million51.86 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4063.75 million49.58 millionOptionable

Recent News About These Companies

FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst
HC Wainwright Forecasts Lower Earnings for Vera Therapeutics
Evercore ISI Remains a Buy on Vera Therapeutics (VERA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cryoport stock logo

Cryoport NASDAQ:CYRX

$6.68 -0.05 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$6.67 -0.01 (-0.15%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$11.83 +0.09 (+0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$11.83 0.00 (0.00%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$25.17 +0.74 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$25.30 +0.13 (+0.50%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$21.25 -0.08 (-0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$21.24 -0.01 (-0.05%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.